Updates on triple-negative breast cancer and immunotherapy

Best of ASCO Miami 2023

7 - 8 Jul 2023

Published: 7 Jul 2023

Rating:

Save

Dr Avan Armaghani - Moffitt Cancer Center, Tampa, USA

Dr Avan Armaghani speaks to ecancer about the updates on triple-negative breast cancer and immunotherapy.

She says that her talk at the best of ASCO Miami 2023 is an overview of what is being done currently in the treatment of metastatic triple-negative breast cancer and what’s coming up on the horizon.

In the neoadjuvant setting, chemotherapy in combination with immunotherapy is the new standard of care in stage 2 and 3 triple-negative breast cancer and in metastatic triple-negative breast cancer, immunotherapy and antibody-drug conjugates are being used as part of the treatment regimen.

She concludes by talking about what to expect in the future.

What was your talk about?

My talk is really an overview of currently what we’re doing in the treatment in both neoadjuvant and metastatic triple negative breast cancer and then what’s coming up on the horizon. So really in the neoadjuvant space, chemotherapy in combination with immunotherapy being the new standard of care in stage 2 and 3 triple negative breast cancer.

Then in metastatic triple negative breast cancer we’ve come a long way from just chemotherapy to now the use of immunotherapy and antibody-drug conjugates as part of our treatment regimen.

What advances can we expect in the future?

Definitely. In the neoadjuvant space there’s a lot of work looking at how we can de-escalate therapy, potentially being able to eliminate the need for anthracyclines and using other chemo combinations with immunotherapy. In the metastatic setting various combinations of immunotherapy with antibody-drug conjugates, even in the first-line setting. So a lot of exciting advancements in the near future for sure.